Can AI bring more order to amyloid scans? In the February 11 Alzheimer’s & Dementia, scientists led by Pierrick Bourgeat at CSIRO Australian eHealth Research Center, Brisbane, and Vincent Doré of ...

This noninvasive approach attempts to modulate the noradrenergic system of the locus coeruleus by stimulating the vagal nerve. It uses electrodes clipped on the outer ear to stimulate the auricular ...

This humanized IgG1 antibody inhibits an immune checkpoint protein called programmed death ligand, aka PD-L1, stimulating the immune system. Checkpoint inhibitors, including other antibodies, are ...

News Peptide Brace Against AD—Insulin, Neuropeptide Y Tame Aβ Toxicity 10 Feb 2009 Aβ and Phospho-tau: Strange Bedfellows Get Intimate at Synapses 19 Sep 2008 The Skinny on FAT: APP’s Role in Fast ...

THY-Tau22 mice are a model for tau aggregation, a pathological hallmark of Alzheimer's disease as well as numerous tauopathies. With age these mice develop a variety of tau-related neuropathological ...

It has been clear for a while that anti-amyloid antibodies can sweep plaque from the brain, but until now the question of whether this slows cognitive decline has remained hotly contended. Despite ...

Some evidence suggests that regular consumption of fish, nuts, fruits, veggies, and whole grains, aka the Mediterranean diet, reduces a person’s risk of dementia. APOE4, on the other hand, increases ...

This database is a repository of normal genetic variability, designed to be a tool for researchers who study neurodegenerative disease. It contains whole-exome sequencing results from nearly 500 ...

In a watershed moment for the field, the U.S. Food and Drug Administration today approved the first Alzheimer’s treatment that tackles the underlying disease pathology. Biogen and Eisai’s anti-amyloid ...

The Alzheimer’s field was rocked this week by allegations against Sylvain Lesné at the University of Minnesota, Minneapolis. Lesné stands accused of manipulating data images in multiple papers, ...

On November 24, Novo Nordisk announced that the GLP-1 mimetic semaglutide had failed to slow progression of Alzheimer’s disease in two Phase 3 trials. Even though the cat was out of the bag, ...

Just as fluid biomarkers for amyloidosis and tau have revolutionized clinical studies of Alzheimer’s disease, α-synuclein markers are poised to do the same for Parkinson’s. With the advent of ...